Metastatic cancer

Common Name(s)

Metastatic cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Metastatic cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Metastatic cancer" returned 5255 free, full-text research articles on human participants. First 3 results:

Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
 

Author(s): Lin Shui, Yu-Shen Wu, Huapeng Lin, Pixian Shui, Qin Sun, Xiaopin Chen

Journal: Cell. Physiol. Biochem.. 2018 ;48(5):1870-1881.

 

Conversion therapy can convert unresectable metastatic colorectal cancer (mCRC) into resectable. However, the optimal conversion regimen was not yet defined. This meta-analysis aimed to compare the efficacy and safety of the triplet chemotherapy (FOLFOXIRI) plus bevacizumab (Bev) ...

Last Updated: 31 Dec 1969

Go To URL
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.
 

Author(s): Guido Giordano, Antonio Febbraro, Erica Quaquarini, Anna Turletti, Rebecca Pedersini, Mimma Raffaele, Federica Villa, Rosalba Rossello,

Journal: Oncology. 2018 ;94 Suppl 1():34-44.

 

Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy. However, no standard approach has been ...

Last Updated: 31 Dec 1969

Go To URL
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
 

Author(s): Rita De Sanctis, Elisa Agostinetto, Giovanna Masci, Emanuela Ferraro, Agnese Losurdo, Alessandro Viganò, Lidija Antunovic, Monica Zuradelli, Rosalba Maria Concetta Torrisi, Armando Santoro

Journal: Oncology. 2018 ;94 Suppl 1():19-28.

 

Predictive factors of response to eribulin are lacking. We aimed to investigate the activity and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response.

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Metastatic cancer" returned 599 free, full-text review articles on human participants. First 3 results:

Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis.
 

Author(s): Baoshan Di, Bei Pan, Long Ge, Jichun Ma, Yiting Wu, Tiankang Guo

Journal: Medicine (Baltimore). 2018 Mar;97(13):e0115.

 

Pancreatic cancer (PC) is a devastating malignant tumor. Although surgical resection may offer a good prognosis and prolong survival, approximately 80% patients with PC are always diagnosed as unresectable tumor. National Comprehensive Cancer Network's (NCCN) recommended gemcitabine-based ...

Last Updated: 31 Dec 1969

Go To URL
Recent advances in medical therapy for metastatic urothelial cancer.
 

Author(s): Takeshi Yuasa, Shinji Urakami, Junji Yonese

Journal: Int. J. Clin. Oncol.. 2018 Aug;23(4):599-607.

 

Cytotoxic chemotherapy has been the mainstay of medical therapy for metastatic urothelial cancer. Currently, the gemcitabine/cisplatin regimen is widely used worldwide as the standard first-line medical treatment. Very recently, in 2017, pembrolizumab, a highly selective, humanized ...

Last Updated: 31 Dec 1969

Go To URL
Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.
 

Author(s): Juan Pablo Sade, Carlos Alberto Vargas Báez, Martin Greco, Carlos Humberto Martínez, Miguel Ángel Álvarez Avitia, Carlos Palazzo, Narciso Hernández Toriz, Patricia Isabel Bernal Trujillo, Diogo Assed Bastos, Fabio Augusto Schutz, Santiago Bella, Lucas Nogueira, Neal D Shore

Journal:

 

Prostate cancer is a significant burden and cause of mortality in Latin America. This article reviews the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and provides consensus recommendations to assist Latin American prostate cancer specialists ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 3 Aug 2018

Go to URL
Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.
 

Status: Recruiting

Condition Summary: Metastatic Cancer

 

Last Updated: 15 Feb 2017

Go to URL